Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $127.50 | Total: $637.50 |
| 1 | 10 | $108.00 | Total: $1,080.00 |
| 1 | 25 | $91.50 | Total: $2,287.50 |
| 1 | 50 | $78.00 | Total: $3,900.00 |
| 1 | 100 | $67.50 | Total: $6,750.00 |
Overview
VX-984 (M9831) is an oral, selective DNA-PK inhibitor that can cross the blood-brain barrier. VX-984 inhibited the conjugation of non-homologous terminal NHEJ and acted on DSBs to break DNA double strand. VX-984 is commonly seen in glioblastoma (GBM) and non-small cell lung cancer (NSC-LC) studies.
Chemical Properties
| Molecular Formula | C23H21D2N7O |
| Molecular Weight | 415.49 |
| CAS Numbers | 1476074-39-1 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [2H]c1nc(C)nc([2H])c1-c1cc(NC[C@@H](C)c2cccc3c(ccnc23)C(=O)NC)ncn1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Atif J Khan, et al. VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells. Oncotarget. 2018 May 25;9[40] 25833-25841.